Lakefront Biotherapeutics (LKFT) Non-Current Deferred Tax Liability (2022 - 2025)

Lakefront Biotherapeutics (LKFT) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $20.2 million in Q2 2025.

• Non-Current Deferred Tax Liability for Q2 2025 came in at $20.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $20.2 million (changed N/A YoY), and the FY2024 annual result was $22.1 million, down 13.08% from the prior year.
• Non-Current Deferred Tax Liability climbed to $20.2 million in Q2 2025 per LKFT's latest filing, from $19.7 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $27.6 million in Q3 2023 and troughed at $19.7 million in Q1 2025.
• A 4-year average of $22.7 million and a median of $22.1 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability climbed 23.56% in 2023, then declined 20.26% in 2025.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $20.6 million in 2022, then rose by 23.56% to $25.4 million in 2023, then slipped by 13.08% to $22.1 million in 2024, then fell by 8.34% to $20.2 million in 2025.
• Business Quant data shows LKFT's Non-Current Deferred Tax Liability at $20.2 million in Q2 2025, $19.7 million in Q1 2025, and $22.1 million in Q4 2024.